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Summary
Injecting behaviour in people who inject drugs is the main risk factor for hepatitis Not being on opiate substitution therapy (OST) was associated with a statistically significant decrease in injecting frequency, χ 2 (1) = 10.412, P = 0.001, as was having a partner who also used drugs, in particular when that partner was also on treatment for HCV infection, Z = −2.312, P = 0.021. Treating a hard-to-reach population for HCV infection is not only possible, but also bears health benefits beyond treatment of HCV alone. Enrolling couples on HCV treatment when partners are sero-concordant has shown enhanced benefits for reduction in injecting behaviour. Implications for practice are discussed.
K E Y W O R D S
hepatitis C, injecting behaviour, opiate substitution therapy, partner, people who inject drugs partner who also injects, trust and risk perception to name a few. However, they found no changes in daily injecting, use of sterile or shared equipment. 17 Only a few studies have investigated the effects of HCV treatment on risk behaviour 16, 17 and no literature to date has investigated the role of psychosocial factors such as romantic partnerships and living situation on risk behaviour during and following HCV treatment.
The Eradicate-C study was carried out to investigate the effectiveness of interferon-based HCV treatment on current PWID, characterized by a strenuous lifestyle and erratic engagement with healthcare services. This study aimed to investigate changes in injecting behaviour during treatment, examining the role of psychosocial factors on hypothesized injecting behaviour change. 
| ME THODS

| Study design
| Outcomes
The primary outcome of the Eradicate-C study was to analyse SVR12 in the PWID population, which resulted in an 81.1% genotype 1 and 82.5% genotypes 2 and 3 achieving SVR. The total SVR12 rate for all participants was 81.9%.
In this paper, the outcomes of interest were the behavioural and 
| Study participants
| Analysis
Data were analysed using IBM SPSS Statistics 22. Descriptive analyses were run to obtain characteristics of the sample. If data were missing for one visit (eg., visit 8) but available for immediately preceding and subsequent weeks (eg., visits 7 and 9), an average score was used for the required missing visit. If immediately preceding and subsequent visit scores were not available, data were considered missing. Non-parametric testing was selected following data testing for violation of normality, which showed skewed data with kurtosis at all time points. A square root transformation was attempted to normalize distributions and eliminate outliers, but distribution remained skewed. Outliers were included in the analysis as nonparametric use of medians signifies outliers hold less influence over test results. The null hypothesis (no difference in injecting frequency at different time points) was tested with a non-parametric Friedman test, and subsequent post hoc analyses using Wilcoxon signed-rank tests were run to identify where differences lay.
Effect size r was calculated with Rosenthal's formula r =
where Z is the post hoc Wilcoxon signed-rank test score and N is the number of observations. The coefficient r is more commonly used as a correlation coefficient to measure the strength of a relationship;
however, it is a versatile coefficient and it is used, especially within non-parametric testing, as a measure of experimental effect. 19 Once identified that the largest injecting frequency difference was observed between week 1 and week 8 of the study, this difference was used to create a new dependent variable of injecting change, used in the analysis both as a categorical variable, to allow for Crosstab explorations using multiple categorical social factors, and as a continuous variable, to allow investigation of significant differences between the most important categorical social factors using Mann-Whitney U tests.
| RE SULTS
A total of 106 participants consented to treatment. Two never completed baseline measures: 1 participant did not meet inclusion criteria and 1 participant died before starting treatment and completing baseline data. Of the remaining 104 consented, 94 completed treatment, but only 84 had completed behavioural and social data. Ten participants never commenced treatment: 3 spontaneously cleared the infection, 4 were lost to follow-up, 2 were treated on standard pathway after becoming drug-free, and 1 was in prison out-with the catchment area. The remaining 10 consented participants who completed treatment had data missing for the visit 8 follow-up and were therefore not included in this sub-study analysis. Characteristics of participants at enrolment are presented in Table 1 . informative. There are three variables which make significance on chi-squared: On OST, Has children and Has partner. Table 2 .
Week 8 was the time point at which the largest decrease in injecting was observed. Figure 1 shows the difference in mean injecting frequency between week 1 and week 8 of treatment among the grouping variables analysed above.
Chi-square tests were run to explore associations between participant characteristics and injecting behaviour change as judged by the new variable Better or Not Better (Table 3) . Odds ratio for the association between having a partner who used drugs and "Better" The difference between week 1 and week 8 injecting frequency was computed and categorized as "Better" for a difference of ≥ 7or "Not Better" otherwise. * Significant at P < 0.05. M = 5.65 (95% CI: −0.23 to 11.54; Figure 1 ). These results were confirmed by analysing the association between the injecting frequency difference between week 1 and week 8 in couple members. Couples were assigned a couple ID. All couples were heterosexual. The malefemale Pearson's correlation coefficient was r = 0.629, P = 0.038, which meant that when males reduced their injecting, so did their female partners and vice versa.
| D ISCUSS I ON
The findings of this paper show a significant reduction in injecting frequency between baseline, that is before the start of HCV treatment, and every other time point. The largest reduction was recorded between week 1 (baseline) and week 8, with injecting frequency stabilizing thereafter whilst on treatment.
Possible mechanisms of behaviour change were explored using baseline social factors.
| Benefits for non-OST patients
Firstly, not being on OST on week 2 of treatment (first treatment visit recording this information) was found to be associated with a significant reduction in injecting frequency. It has been widely dem- On the other hand, those who were not on OST on week 2 of Eradicate-C had not experienced the behavioural benefits of OST before their engagement with HCV treatment. It is well recognized that PWID are reluctant to access healthcare services, generally due to a lack of material resources, complicated and lengthy referral pathways, experience of stigma and poor relationship with healthcare providers. [24] [25] [26] [27] For these individuals who were not on OST, engagement with HCV nurses might have been the only contact with any healthcare provider. Given the regular and considerate nature of this contact, a therapeutic relationship with the nurses providing the HCV treatment might have functioned as a behaviour change mechanism these patients had not experienced because not enrolled on OST. Therapeutic alliance was not measured in this study, yet previously published literature attests for the importance of this factor on healthcare outcomes relating to this population. [28] [29] [30] [31] Meta-analyses have shown positive therapeutic alliance to increase patients' engagement and retention within drug services, as well as motivation, treatment readiness and treatment experience. 31 The results of this study suggest a possible negative correlation between engagement in HCV treatment and injecting behaviour frequency in populations who have minimum contact with other healthcare services.
| Behaviour change in intimate partnerships
The observed reduction in weekly injecting frequency was also linked to drug-using status of romantic partners. Those who had a partner who used drugs were more likely to reduce their injecting frequency, a reduction difference of more than nine injections a In the general population, the health benefits of being married or in a committed intimate relationship are well documented. 14, 15 People in romantic partnerships tend to be healthier, engage with healthcare services and show a longer lifespan. 15 The role of intimate partnerships within the drug-using population, however, has often been linked to increased risk-taking behaviour and generally has been viewed as a bad influence on health. 14, [32] [33] [34] [35] Qualitative studies have shown that HCV management within couples could help consolidate a relationship, introducing sentiments such as feeling valued and cared for. 14 PWID generally experience hostile social environments, and intimate partnerships which involve sentiments such as those above might represent one of the only types of meaningful social support and care that PWID encounter. 14 Social support is regarded as an essential part of HCV treatment, with many care pathways for PWID involving the role of a peer support worker as integral part of the treatment, 36 providing empathy and trustworthiness to patients on treatment. However, it is not simply individualistic social support perception that has to be considered to explain the study findings.
Lewis' couples' interdependence theory 15 explains how motivation transformation can occur when partners experience a health event which is not only significant for the self, but has cognitive and emotional significance for the relationship. The attribution of significance of the health event to the dyad rather than the individual is the result of automatic consideration of partnership roles, subjective norms, commitment, quality of the relationship and trust. 15 HCV infection is a health threat that has both emotional and cognitive implications on the relationship and on each partner. These implications help transform motivation from "individual-focused" to "relationship-focused," adding a layer of complex interplay between intrapersonal and interpersonal behaviour change processes. Once motivation has become "relationship-focused," couples work together through communal coping to achieve better health through shared action to manage the health threat. 15, 37 Communal coping requires shared beliefs that is reducing injecting frequency will ensure HCV is less likely to recur in the couple, will influence the behavioural outcome. The responsibility of the couples' (and individual) health therefore lies equally on both partners, enabling the couple to become the unit for risk-reducing behaviour change. 14, 15 Associations between changes in self-perception and self-care have been identified before. 12, 38 Often these self-perceptions are intended as the "self"
as an "addict" becoming the "self" as a "patient worthy of HCV treatment". 12, 14 A similar process of psychological alteration might take place within the couple, with the couple's identity changing from "drug-using partners" to "HCV-treated partners, who coped with effects of treatment and achieved SVR as a unit," presenting a shared sense of "self."
| Reinfection
One PYFU. These recurrence rates led to a summary 5-year risk of 0.95%, 10.67% and 15.02%, respectively.
42
Reducing injecting risk behaviour is the first step to reduce the risk of HCV reinfection after successful treatment. Reducing injecting behaviour within romantic partnerships could have particular benefits in preventing reinfection, given the widespread injecting equipment sharing practices among sexual partners. The observed injecting frequency reduction within couples during treatment in this study would seem to suggest a transitive relation between treating couples in a romantic partnership and a reduced risk of reinfection, with the reduced injecting behaviour as the linking factor. This will be investigated in future reinfection studies.
| CON CLUS IONS
This study shows that treating a hard-to-reach population for HCV infection is not only possible, but also suggests health benefits beyond treatment of HCV alone. A significant reduction in injecting be- Shorter treatment times and ease of treatment might also affect the quality of the therapeutic relationship established between hard-toreach patients and healthcare provider. Once again, this might impact on the hereby observed injecting behaviour change. However, the notion of HCV treatment alone, rather than the hardship endured or the length of treatment time, might be enough to kick-start the motivational transformation within an intimate partnership and effects on communal coping and risk behaviour reduction could still be observed in the DAA treatment era. Further research on similar populations being treated with IFN-free DAA is needed in order to shed light on the generalizability of these results.
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